Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1733813

registered interest
date	14/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prostate Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) encourage screening for and (b) increase the rate of early diagnosis of prostate cancer.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	8772
answer	answer is ministerial correction date of answer 17/10/2024 answer text <p>Screening for prostate cancer is currently not recommended by the UK National Screening Committees (UK NSC). This is because of the inaccuracy of the current best test Prostate Specific Antigen (PSA). A PSA-based screening programme could harm men as some of them would be diagnosed with a cancer that would not have caused them problems during their life. This would lead to additional tests and treatments which can also have harmful side effects.</p><p>The Department has invested £16 million in the TRANSFORM trial which seeks to find ways to diagnose prostate cancer as early as possible. This trial will compare the most promising tests to look for prostate cancer in men that do not have symptoms and aim to address disparities in early detection rates across different groups.</p><p>We are also working with NHS England to support the National Health Service to meet the Faster Diagnosis Standard for cancer to be diagnosed or ruled out within 28 days from an urgent suspected cancer referral. This includes introducing best practice timed pathways for prostate cancer to streamline diagnostic pathways and speed up diagnoses.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 17/10/2024 16:31:02 answering member 1506 label Biography information for Andrew Gwynne
tabling member	1447 label Biography information for Andrew Rosindell

1730052

registered interest
date	04/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Cancer: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to support research on (a) the causes of and (b) treatments for metastatic lung cancer.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	5895
answer	answer is ministerial correction date of answer 14/10/2024 answer text <p>Research is crucial in tackling cancer, which is why the Department invests over £1.5 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121.8 million in 2022/23. The NIHR spends more on cancer than any other disease group, reflecting its high priority.</p><p>The NIHR also invests in research infrastructure to support the delivery of research. This includes research into a novel cancer vaccine for lung cancer patients that primes the immune system to recognise and fight cancer cells.</p><p>The NIHR welcomes funding applications for research into any aspect of human health, including lung cancer. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. The NIHR welcomes further high-quality proposals to understand the causes of and to inform approaches to treating metastatic lung cancer.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 14/10/2024 11:50:42 answering member 1506 label Biography information for Andrew Gwynne
tabling member	1447 label Biography information for Andrew Rosindell

1730059

registered interest
date	04/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Bowel Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much funding his Department has provided for the early detection of bowel cancer in the 2024-25 financial year.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	5902
answer	answer is ministerial correction date of answer 14/10/2024 answer text <p>We will get the National Health Service catching cancer, including bowel cancer, on time, diagnosing it earlier, and treating it faster so more patients survive this horrible set of diseases.</p><p>The NHS will maximise the pace of the roll-out of additional diagnostic capacity, delivering the final year of the three-year investment plan for establishing Community Diagnostic Centres (CDCs), and ensuring timely implementation of new CDC locations and upgrades to existing CDCs, with capacity prioritised for cancer diagnostics.</p><p>The NHS bowel screening budget in FY24/25 is £293 million. Furthermore, in 2024/25, we will continue to extend the NHS Bowel Cancer Screening Programme to additional cohorts, specifically 50 to 52 year olds.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 14/10/2024 14:25:34 answering member 4444 label Biography information for Karin Smyth
tabling member	1447 label Biography information for Andrew Rosindell

1730061

registered interest
date	04/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dentistry: Recruitment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help increase the recruitment of NHS dentists.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	5904
answer	answer is ministerial correction date of answer 11/10/2024 answer text <p>We will tackle the immediate dentistry crisis with a rescue plan to provide 700,000 more urgent dental appointments and to recruit new dentists to the areas that need them most. To rebuild dentistry in the long term, we will reform the dental contract, with a shift to focus on prevention and the retention of National Health Service dentists.</p><p>We acknowledge that there are areas of the country that are experiencing recruitment and retention issues, and we are taking steps to address the workforce challenges across the country. Integrated care boards have started to advertise posts through the Golden Hello scheme. This recruitment incentive will see up to 240 dentists receiving payments of £20,000 to work in those areas that need them most, for three years.</p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered 11/10/2024 09:31:29 answering member 4359 label Biography information for Stephen Kinnock
tabling member	1447 label Biography information for Andrew Rosindell

1730064

registered interest
date	04/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services: Romford
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of dental provision in Romford constituency.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	5907
answer	answer is ministerial correction date of answer 11/10/2024 answer text <p>The data for the NHS North East London Integrated Care Board, which includes the Romford constituency, shows that 46% of adults were seen by a National Health Service dentist in the previous 24 months, compared to 40% in England. Additionally, 57% of children were seen by an NHS dentist in the previous 12 months, compared to 56% in England. These statistics were published by the NHS Business Services Authority on 22 August 2024, and are available at the following link:</p><p><a href="https://www.nhsbsa.nhs.uk/statistical-collections/dental-england/dental-statistics-england-202324" target="_blank">https://www.nhsbsa.nhs.uk/statistical-collections/dental-england/dental-statistics-england-202324</a></p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered 11/10/2024 09:33:48 answering member 4359 label Biography information for Stephen Kinnock
tabling member	1447 label Biography information for Andrew Rosindell

1729346

registered interest
date	12/09/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antidepressants: Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to reduce prescriptions for anti-depressant medication.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	5539
answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>Overprescribing can be addressed by taking a shared decision-making approach and optimising a person's medicines, and by ensuring that patients are prescribed the right medicines at the right time, in the right doses.</p><p>NHS England has published Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: framework for action. It aims to further reduce inappropriate prescribing of medicines which can cause withdrawal, such as anti-depressants, where they may no longer be the most clinically appropriate treatment for patients and alternatives to medicines may be equally or more appropriate. More information on the framework is available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/" target="_blank">https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/</a></p><p>NHS England provides support to integrated care boards (ICBs) and primary care as the Framework is implemented. For example, there is National medicines optimisation opportunities for the NHS, which includes an opportunity for addressing inappropriate antidepressant prescribing, with more information available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/" target="_blank">https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/</a></p><p>There is also Specialist Pharmacy Service advice on deprescribing antidepressants, for which more information is available at the following link:</p><p><a href="https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/" target="_blank">https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/</a></p><p>There is annual investment of £2.3 billion until 2024 in mental health services and NHS Talking Therapies for anxiety and depression (which delivered 670,000 courses of treatment in 2022/23). More information is available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23</a></p><p>There is also a national programme to ensure social prescribing is an option for patients, as well as funding for social prescribers through the Additional Roles Reimbursement Scheme (ARRS). More information is available at the following links:</p><p><a href="https://www.england.nhs.uk/personalisedcare/social-prescribing/" target="_blank">https://www.england.nhs.uk/personalisedcare/social-prescribing/</a></p><p><a href="https://www.england.nhs.uk/gp/expanding-our-workforce/" target="_blank">https://www.england.nhs.uk/gp/expanding-our-workforce/</a></p><p>There is also support for delivering Structured Medication Reviews, including those on medicines associated with dependence and withdrawal symptoms), via: Health Innovation Network training to help build GP and prescribing health care professionals' confidence in, and understanding of, the complex issues surrounding stopping inappropriate medicines safely. Guidance is also published by NHS England on Structured Medication Review and Medicines Optimisation, which is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/" target="_blank">https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/</a></p><p>Offering treatments that are not medicines is also key to addressing overprescribing. Many other initiatives delivered across the National Health Service contribute towards this.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 5540 5544 question first answered 08/10/2024 13:22:18 answering member 4444 label Biography information for Karin Smyth
tabling member	1447 label Biography information for Andrew Rosindell

1729347

registered interest
date	12/09/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antidepressants: Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to publish guidance to GPs on reducing prescriptions for anti-depressant medication.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	5540
answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>Overprescribing can be addressed by taking a shared decision-making approach and optimising a person's medicines, and by ensuring that patients are prescribed the right medicines at the right time, in the right doses.</p><p>NHS England has published Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: framework for action. It aims to further reduce inappropriate prescribing of medicines which can cause withdrawal, such as anti-depressants, where they may no longer be the most clinically appropriate treatment for patients and alternatives to medicines may be equally or more appropriate. More information on the framework is available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/" target="_blank">https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/</a></p><p>NHS England provides support to integrated care boards (ICBs) and primary care as the Framework is implemented. For example, there is National medicines optimisation opportunities for the NHS, which includes an opportunity for addressing inappropriate antidepressant prescribing, with more information available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/" target="_blank">https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/</a></p><p>There is also Specialist Pharmacy Service advice on deprescribing antidepressants, for which more information is available at the following link:</p><p><a href="https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/" target="_blank">https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/</a></p><p>There is annual investment of £2.3 billion until 2024 in mental health services and NHS Talking Therapies for anxiety and depression (which delivered 670,000 courses of treatment in 2022/23). More information is available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23</a></p><p>There is also a national programme to ensure social prescribing is an option for patients, as well as funding for social prescribers through the Additional Roles Reimbursement Scheme (ARRS). More information is available at the following links:</p><p><a href="https://www.england.nhs.uk/personalisedcare/social-prescribing/" target="_blank">https://www.england.nhs.uk/personalisedcare/social-prescribing/</a></p><p><a href="https://www.england.nhs.uk/gp/expanding-our-workforce/" target="_blank">https://www.england.nhs.uk/gp/expanding-our-workforce/</a></p><p>There is also support for delivering Structured Medication Reviews, including those on medicines associated with dependence and withdrawal symptoms), via: Health Innovation Network training to help build GP and prescribing health care professionals' confidence in, and understanding of, the complex issues surrounding stopping inappropriate medicines safely. Guidance is also published by NHS England on Structured Medication Review and Medicines Optimisation, which is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/" target="_blank">https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/</a></p><p>Offering treatments that are not medicines is also key to addressing overprescribing. Many other initiatives delivered across the National Health Service contribute towards this.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 5539 5544 question first answered 08/10/2024 13:22:18 answering member 4444 label Biography information for Karin Smyth
tabling member	1447 label Biography information for Andrew Rosindell

1729348

registered interest
date	12/09/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antidepressants: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to provide funding for medical research into alternatives to antidepressant medication.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	5541
answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR funds an extensive portfolio of mental health research, including a number of investments focused on alternatives to antidepressant medication. For example, the NIHR Oxford Health Biomedical Research Centre has a dedicated research theme on depression therapeutics and human neurocognitive models of antidepressant action. Additionally, the NIHR invested £1.1 million in a randomised controlled trial to examine if it is feasible, safe, and effective to use psilocybin to treat people with treatment-resistant depression, which was supported by the NIHR King’s Clinical Research Facility and the NIHR Maudsley Biomedical Research Centre. The study was completed in February 2024 and the full results will be published following peer review. The NIHR welcomes funding applications for research into any aspect of human health, including alternatives to antidepressant medication.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 08/10/2024 14:52:29 answering member 1506 label Biography information for Andrew Gwynne
tabling member	1447 label Biography information for Andrew Rosindell

1729349

registered interest
date	12/09/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antidepressants: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help treat people who have had adverse reactions to antidepressant medication including to (a) selective serotonin reuptake inhibitors and (b) serotonin and norepinephrine reuptake inhibitors.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	5542
answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency approved Patient Information Leaflets outline the details of possible adverse reactions associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors, and highlight when the advice of a healthcare professional should be sought for specific serious adverse reactions.</p><p>People who are concerned about adverse reactions to antidepressants should speak to a healthcare professional. Suspected adverse reactions to medicines, including antidepressant medication, can be reported through the Yellow Card Scheme, which is the system for recording adverse reactions suspected to be associated with medicines and medical devices in the United Kingdom.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 08/10/2024 15:03:57 answering member 4444 label Biography information for Karin Smyth
tabling member	1447 label Biography information for Andrew Rosindell

1729350

registered interest
date	12/09/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antidepressants: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to treat people who have (a) post-acute withdrawal syndrome and (b) post-SSRI sexual dysfunction after taking anti-depressant medication.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	5543
answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) approved product information outlines the details of possible adverse reactions associated with each medicine. Whilst post-acute withdrawal syndrome is not currently recognised as being associated with antidepressant use, the product information for the most commonly prescribed antidepressants contain advice about the risk of withdrawal reactions associated with antidepressant use, and advises users not to stop these types of medication abruptly.</p><p>The product information for some antidepressants contains advice that they can be associated with sexual dysfunction where symptoms continue despite stopping the antidepressant. An expert working group of the Commission on Human Medicines has been established to review how the risk of sexual dysfunction, where symptoms may continue, is communicated to patients. Separately, a review of the communication of the risk of withdrawal reactions in the product information will be taken forward in the MHRA’s project, to improve the information supplied with known dependency-forming medicines. Patients can visit either their general practice, or a sexual health clinic, for support with erectile dysfunction.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 08/10/2024 15:04:58 answering member 4444 label Biography information for Karin Smyth
tabling member	1447 label Biography information for Andrew Rosindell